Immunotherapy in Lung Cancer | Specialty

The OncLive Immunotherapy in Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in lung cancer. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment in non–small cell lung cancer and small cell lung cancer.

PD-L1 Status Stratifies Immunotherapy Treatment in NSCLC

November 25th 2020

Data from completed studies evaluating immunotherapy in lung cancer alone or in combination with chemotherapy show that a breakdown of populations by PD-L1 status and additional considerations such as toxicity profiles should guide treatment decisions.

KEYNOTE-598 Trial Examining Pembrolizumab/Ipilimumab in NSCLC Stopped for Futility

November 10th 2020

The phase 3 KEYNOTE-598 trial evaluating the dual immunotherapy combination comprised of pembrolizumab and ipilimumab as frontline treatment in patients with metastatic non–small cell lung cancer who have a PD-L1 tumor proportion score of 50% or greater and do not harbor any EGFR or ALK aberrations has been discontinued.

Management of Small Cell Lung Cancer Moves Forward With Immunotherapy

November 7th 2020

Frontline chemoimmunotherapy trials represent a critical milestone in extensive-stage small cell lung cancer, but one that requires better understanding of the methods that can be used to broaden the patient population in whom durable benefit is currently concentrated.

Borghaei Stresses Importance of Immunotherapy Biomarkers in Frontline Advanced NSCLC Treatment

October 26th 2020

Hossein Borghaei, DO, MS, further discusses the benefit of immunotherapy combinations, the potential of tiragolumab, and the need for better biomarkers to guide treatment in NSCLC.

The Future of Lung Cancer Treatment

October 26th 2020

Mesothelioma: A Look at DREAM3R and PrECOG Trial

October 26th 2020

Fundamentals of Mesothelioma

October 26th 2020

Trials in Limited-Stage Small-Cell Lung Cancer

October 26th 2020

Treatment for Progressive Small-Cell Lung Cancer

October 26th 2020

Treatment Options in Small–Cell Lung Cancer

October 26th 2020

Recent Advances in Small-Cell Lung Cancer

October 26th 2020

Treatment for PD-L1 High/Low/Negative Non–Small Cell Lung Cancer

October 26th 2020

Understanding Immune Response in Non–Small Cell Lung Cancer

October 26th 2020

Chemotherapy and Immunotherapy in Non–Small Cell Lung Cancer

October 26th 2020

Treatment Options in PD-L1 Positive Non–Small Cell Lung Cancer

October 26th 2020

Treatment Efficacy in Non–Small Cell Lung Cancer

October 26th 2020

Frontline Treatment in Non–Small Cell Lung Cancer

October 26th 2020

Immunotherapy Combos Continue to Excel in NSCLC, But Patient Selection Must Be Optimized

October 23rd 2020

In an interview with OncLive® Michael Shafique, MD, discusses examples of this groundbreaking research of immunotherapy combinations in NSCLC.

Evaluating New Standards in Extensive-Stage Small Cell Lung Cancer

October 23rd 2020

Igor I. Rybkin, MD, PhD, discusses the data with these frontline and second-line regimens in extensive-stage small cell lung cancer.

Navigating Newfound Options in SCLC With Immunotherapy and Lurbinectedin

October 16th 2020

Rafael Santana-Davila, MD, discusses the introduction of immunotherapy and lurbinectedin to the SCLC armamentarium, as well as areas in need of additional research.